Comprehensive Monograph on Abrocitinib (Cibinqo®)

Executive Summary

Abrocitinib, marketed under the brand name Cibinqo®, is an oral, small-molecule, selective Janus Kinase 1 (JAK1) inhibitor developed by Pfizer. It represents a significant advancement in the systemic treatment of atopic dermatitis (AD), a chronic inflammatory skin disease. This report provides a comprehensive analysis of abrocitinib, encompassing its chemical synthesis, pharmacological profile, clinical evidence, regulatory status, and strategic position in the therapeutic landscape.

The primary approved indication for abrocitinib is for the treatment of moderate-to-severe atopic dermatitis in adolescents (aged 12 and older) and adults. Regulatory approvals vary slightly by region, with the U.S. Food and Drug Administration (FDA) specifying its use in patients with refractory disease who have failed other systemic therapies, while the European Medicines Agency (EMA) approves it for patients who are candidates for systemic therapy. Abrocitinib is administered as a once-daily oral tablet.

Pharmacologically, abrocitinib functions by selectively inhibiting JAK1, thereby disrupting the signaling cascades of key pro-inflammatory cytokines implicated in AD pathogenesis, including Interleukin-4 (IL-4), IL-13, and IL-31. Its selectivity for JAK1 over other JAK family members, particularly JAK3, is a key feature of its design, intended to optimize its immunomodulatory effects while potentially mitigating certain side effects associated with less selective JAK inhibition. The drug is rapidly absorbed and extensively metabolized by hepatic CYP2C19 and CYP2C9 enzymes into two active metabolites, which, together with the parent compound, constitute the total "active moiety" responsible for the therapeutic effect.

Clinical efficacy has been robustly demonstrated in the global JADE (JAK1 Atopic Dermatitis Efficacy and Safety) development program. Across multiple Phase 3 trials, abrocitinib showed statistically significant and clinically meaningful improvements in skin clearance (measured by EASI and IGA scores) and, most notably, rapid reduction in pruritus compared to placebo. Head-to-head data from the JADE DARE trial established the superiority of the 200 mg dose of abrocitinib over the biologic agent dupilumab in achieving rapid itch relief and early skin clearance, positioning speed of onset as its primary clinical differentiator.

The clinical utility of abrocitinib is balanced by a significant safety profile, highlighted by a class-wide FDA Boxed Warning for JAK inhibitors. This warning underscores the risks of serious infections (bacterial, fungal, and viral, including herpes zoster reactivation), increased all-cause mortality, malignancies, major adverse cardiovascular events (MACE), and thrombosis. These risks, largely extrapolated from a study of another JAK inhibitor in an older rheumatoid arthritis population, necessitate careful patient selection, extensive pre-treatment screening, and ongoing laboratory monitoring, adding a layer of clinical complexity to its use.

Strategically, abrocitinib is positioned as a powerful oral option for patients with severe AD, particularly those suffering from debilitating itch who prioritize rapid symptom control. Its place in therapy is defined by a nuanced discussion between clinician and patient, weighing its rapid efficacy against the long-term safety concerns and monitoring requirements, especially when compared to injectable biologics with different safety profiles. Future research is focused on clarifying long-term risks in the AD population and exploring its potential in other immune-mediated conditions, including food allergies and type 1 diabetes.

Molecular Profile and Chemical Synthesis

A. Drug Identification and Nomenclature

Abrocitinib is a synthetic organic small molecule that has been developed and commercialized for the treatment of inflammatory diseases.[1] It is identified by a consistent set of names and codes across scientific literature, regulatory filings, and commercial branding.

• Generic Name: Abrocitinib [1]
• Brand Name: Cibinqo® [4]
• Developmental Code Name: PF-04965842 [2]
• Drug Type: Small Molecule [1]
• Chemical Class: Abrocitinib is classified as a Janus Kinase (JAK) inhibitor, a targeted immunomodulatory agent.[4] Within broader classifications, it is also referred to as a selective immunosuppressant.[3]

B. Chemical and Physical Properties

The molecular structure and physicochemical properties of abrocitinib define its behavior as a pharmaceutical agent, influencing its formulation, absorption, and interaction with biological systems.

• Chemical Formula: C14​H21​N5​O2​S [7]
• Molecular Weight: The calculated molecular weight is approximately 323.42 g/mol.[10]
• Formal IUPAC Name: N-[cis-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide.[7] The 'cis' designation refers to the stereochemistry of the substituents on the cyclobutyl ring, which is critical for its biological activity.
• Appearance and Solubility: Abrocitinib is a white to pale-colored crystalline powder.[10] It exhibits low solubility in water, measured at 0.04 mg/mL at 25°C, but is soluble in organic solvents like dimethyl sulfoxide (DMSO).[7] Its low aqueous solubility and high permeability classify it as a Biopharmaceutics Classification System (BCS) Class II drug, a profile common for orally administered small molecules that require formulation strategies to ensure consistent absorption.[14]

A comprehensive list of identifiers is crucial for accurate cross-referencing across chemical and pharmacological databases.

Identifier Type	Value	Source(s)
DrugBank ID	DB14973	1
CAS Number	1622902-68-4 (cis-isomer)	7
PubChem CID	78323835	4
UNII (FDA)	73SM5SF3OR	16
EC Number	817-215-8	16
InChI Key	IUEWXNHSKRWHDY-PHIMTYICSA-N	2
Isomeric SMILES	CCCS(=O)(=O)N[C@@H]1CC@@HN(C)c2ncnc3c1cc[nH]2

C. Chemical Synthesis and Development

The journey of abrocitinib from a laboratory concept to a commercially manufactured drug showcases the evolution of synthetic chemistry to meet the demands of safety, efficiency, and scale. The process began with structural modifications of an earlier JAK inhibitor, tofacitinib, ultimately leading to the discovery of PF-04965842.

The initial discovery synthesis, suitable for small-scale laboratory production, involved several key steps. One described route started with a cyclobutyl carbamate, which was condensed with methylamine and reduced to create a cis-isomeric amine intermediate. This intermediate was then coupled with a protected pyrrolopyrimidine moiety, followed by deprotection and final sulfonylation to yield abrocitinib.

For commercial-scale production, this initial pathway was re-engineered to enhance safety and yield, a critical consideration in pharmaceutical manufacturing. The commercial route avoids potentially hazardous reagents and introduces highly efficient, selective steps. The key innovations include:

1. Enzymatic Reductive Amination: The synthesis commences with a commercially available ketoester. In a pivotal step, this starting material undergoes a biocatalytic reductive amination using a custom-engineered enzyme, SpRedAm, derived from Streptomyces purpureus. This enzymatic step is highly stereoselective, producing the crucial cis-aminocyclobutane intermediate with a diastereoisomeric ratio greater than 99:1. This use of biocatalysis represents a "green chemistry" approach, offering high selectivity under mild conditions and avoiding the need for chiral separation or complex stereocontrol with traditional chemical reagents.
2. SNAr Coupling: The resulting amine is then coupled with a chloropyrrolopyrimidine intermediate via a nucleophilic aromatic substitution (SNAr) reaction to form the core structure of the molecule.
3. Lossen Rearrangement: A significant safety and process improvement was the implementation of a Lossen rearrangement. In the lab-scale synthesis, a Curtius rearrangement, which often involves the use of potentially explosive azide intermediates, might be employed. For the commercial route, the ester group of the intermediate is first converted to a hydroxamic acid. This hydroxamic acid is then activated with N,N′-carbonyldiimidazole (CDI), inducing a nitrene-type Lossen rearrangement. This rearrangement proceeds under safer conditions to generate the key diaminocyclobutane intermediate. This method proved robust and scalable, having been used to produce over 600 kg of the intermediate, demonstrating its industrial viability.
4. Final Sulfonylation: The final step is the sulfonylation of the primary amine. To ensure selective reaction and avoid side reactions, a specialized sulfonylation reagent, a 1-propanesulfonyl-1,2,4-triazole derivative, was chosen. This reagent was selected based on its excellent stability in aqueous systems, favorable reaction kinetics, and an acceptable safety profile, making it superior to more reactive reagents like sulfonyl chlorides for large-scale production.

The evolution from a lab-scale synthesis to a refined commercial process highlights the critical, interdisciplinary nature of modern drug development. The strategic decisions to incorporate biocatalysis and replace hazardous reactions with safer alternatives are driven by the need to create a manufacturing process that is not only high-yield but also robust, reproducible, safe for workers, and more environmentally sustainable. These process chemistry innovations are as integral to the drug's ultimate success as its pharmacological properties.

Comprehensive Pharmacological Profile

A. Pharmacodynamics (Mechanism of Action)

Abrocitinib exerts its therapeutic effects through the targeted modulation of intracellular signaling pathways that are central to the inflammatory processes of atopic dermatitis.

Primary Mechanism

The primary mechanism of action of abrocitinib is as a potent and selective inhibitor of Janus Kinase 1 (JAK1). JAKs are a family of intracellular, non-receptor tyrosine kinases that are essential for transducing signals from cytokine and growth factor receptors on the cell surface to the nucleus, thereby regulating gene expression involved in immunity and hematopoiesis.

The canonical JAK-STAT signaling pathway is initiated when a cytokine binds to its specific cell surface receptor, causing the receptor chains to dimerize and bringing the associated JAKs into close proximity. This allows the JAKs to phosphorylate and activate each other. The activated JAKs then phosphorylate tyrosine residues on the intracellular domain of the receptor, creating docking sites for Signal Transducers and Activators of Transcription (STAT) proteins. The recruited STATs are, in turn, phosphorylated by the JAKs, causing them to dimerize. These STAT dimers then translocate to the cell nucleus, where they bind to specific DNA sequences and act as transcription factors to modulate the expression of target genes.

By inhibiting JAK1, abrocitinib effectively blocks this cascade for a specific set of cytokines, preventing the downstream phosphorylation of STATs and subsequent gene transcription that drives the inflammatory response in atopic dermatitis.

Targeted Cytokines in Atopic Dermatitis

The pathogenesis of atopic dermatitis involves a complex interplay of epidermal barrier dysfunction and a dysregulated immune response, particularly driven by Type 2 inflammation. Abrocitinib's efficacy stems from its ability to inhibit the signaling of multiple key cytokines that rely on JAK1, including:

• IL-4 and IL-13: These are hallmark Type 2 cytokines that promote B-cell class switching to IgE, eosinophilic inflammation, and compromise skin barrier function.
• IL-31: Often referred to as the "itch cytokine," IL-31 plays a direct role in pruritus, a primary and debilitating symptom of AD.
• IL-22: This cytokine contributes to epidermal hyperplasia (thickening of the skin) seen in chronic AD lesions.
• Thymic Stromal Lymphopoietin (TSLP): An "alarmin" cytokine released by epithelial cells, TSLP is an upstream activator of the Type 2 inflammatory cascade.

By blocking the JAK1-dependent signaling of this entire group of cytokines, abrocitinib addresses both the inflammatory and pruritic components of the disease. This is supported by clinical data showing that abrocitinib treatment dose-dependently reduces serum levels of inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP), IL-31, and thymus and activation regulated chemokine (TARC).

Kinase Selectivity Profile

A critical aspect of a JAK inhibitor's profile is its selectivity across the four members of the JAK family (JAK1, JAK2, JAK3, and TYK2), as each plays a distinct role in cellular signaling. Abrocitinib was designed as a "second-generation" JAK inhibitor with a high degree of selectivity for JAK1. This selectivity is intended to maximize efficacy by targeting the key pathogenic cytokines while minimizing off-target effects associated with the inhibition of other JAKs. For example, JAK2 is crucial for erythropoietin and thrombopoietin signaling and hematopoiesis, while JAK3 is essential for common gamma-chain cytokine signaling involved in lymphocyte development and function.

In vitro biochemical assays have quantified this selectivity, as summarized in the table below.

Kinase Target	IC₅₀ (nM)	Selectivity Ratio (vs. JAK1)	Source(s)
JAK1	29	1x
JAK2	803	~28x
JAK3	>10,000	>340x
TYK2	1,253	~43x

The high selectivity for JAK1 over JAK3 (>340-fold) is a particularly important design feature. By largely sparing JAK3, abrocitinib was engineered to reduce the risk of broader immunosuppression, such as severe lymphopenia, which can be a concern with less selective JAK inhibitors. While laboratory abnormalities including lymphopenia are still listed as potential side effects, this selectivity profile suggests a more targeted immunomodulatory effect. X-ray crystallography studies have confirmed the binding mode of abrocitinib within the ATP-binding pockets of JAK1 (PDB ID: 6BBU) and JAK2 (PDB ID: 6BBV), providing a structural basis for its inhibitory activity and selectivity.

B. Pharmacokinetics (ADME Profile)

The pharmacokinetic profile of abrocitinib describes its absorption, distribution, metabolism, and excretion (ADME), which collectively determine the drug's concentration over time and inform its dosing regimen.

Absorption

Abrocitinib is rapidly and extensively absorbed following oral administration. Studies show an extent of oral absorption of over 91%, with an absolute oral bioavailability of approximately 60%. Peak plasma concentrations (

Tmax​) are typically reached within 1 hour post-dose, contributing to its rapid onset of action. Steady-state plasma concentrations are achieved within 48 hours of initiating once-daily dosing. The absorption of abrocitinib is not significantly affected by the presence of food, allowing it to be administered with or without meals, which adds to patient convenience.

Distribution

Once absorbed, abrocitinib and its metabolites distribute equally between red blood cells and plasma. The binding to plasma proteins is moderate, with approximately 64% of circulating abrocitinib bound. Its two major active metabolites, M1 and M2, exhibit lower protein binding of approximately 37% and 29%, respectively.

Metabolism

Abrocitinib is eliminated primarily through extensive hepatic metabolism, mediated by the cytochrome P450 (CYP) enzyme system. The major metabolizing enzymes are:

• CYP2C19 (responsible for ~53% of metabolism)
• CYP2C9 (responsible for ~30% of metabolism)

Minor contributions come from CYP3A4 (~11%) and CYP2B6 (~6%). This heavy reliance on CYP2C19 and CYP2C9 is the basis for significant drug-drug interactions and the need for dose adjustments in patients who are genetically poor metabolizers of CYP2C19.

Abrocitinib is converted into several metabolites. Two of these, M1 (3-hydroxypropyl, PF-06471658) and M2 (2-hydroxypropyl), are pharmacologically active and contribute to the drug's overall therapeutic effect. A third major metabolite, M4 (pyrrolidinone pyrimidine), is inactive. The combined, potency-adjusted exposure of unbound parent drug, M1, and M2 is referred to as the

"abrocitinib active moiety" and represents the total pharmacologically active component in circulation.

The existence of these active metabolites is a crucial aspect of the drug's pharmacology. Although abrocitinib and its active metabolites have a relatively short elimination half-life of approximately 3 to 5 hours, the integrated 24-hour exposure (AUC) of the entire active moiety is sufficient to maintain target engagement and support a once-daily dosing regimen. This explains the apparent discrepancy between a short half-life and a convenient dosing schedule. It also underscores why factors affecting metabolism, such as CYP2C19 genetic status or interacting drugs, have such a profound impact on overall drug exposure and necessitate dose adjustments.

Excretion

The body eliminates abrocitinib primarily through the renal excretion of its metabolites. Less than 1% of the administered dose is excreted as the unchanged parent drug in the urine, confirming that metabolic clearance is the dominant elimination pathway. Pharmacokinetic data indicate that over 90% of a dose is expected to be eliminated from the body within 48 hours.

PK Parameter	Value / Description	Source(s)
Oral Bioavailability	~60%
Time to Peak (Tmax)	~1 hour
Time to Steady State	~48 hours
Effect of Food	Not clinically relevant
Plasma Protein Binding	~64% (parent); ~37% (M1); ~29% (M2)
Elimination Half-life (t½)	~3-5 hours (parent and active metabolites)
Primary Metabolic Pathways	CYP2C19 (~53%), CYP2C9 (~30%)
Primary Excretion Route	Renal (as metabolites)

Clinical Efficacy in Moderate-to-Severe Atopic Dermatitis

The clinical development of abrocitinib was anchored by the comprehensive JADE (JAK1 Atopic Dermatitis Efficacy and Safety) global program. These trials systematically evaluated the efficacy and safety of abrocitinib as both monotherapy and in combination with topical therapies, and included direct comparisons with other systemic agents.

A. Analysis of Pivotal Clinical Trials (JADE Program)

The foundational evidence for abrocitinib's approval came from a series of Phase 3, randomized, double-blind, placebo-controlled trials, including JADE MONO-1 and JADE MONO-2. These studies enrolled patients aged 12 and older with moderate-to-severe AD who had an inadequate response to topical therapies.

The primary endpoints were consistently met, demonstrating the superiority of abrocitinib over placebo at week 12. Key efficacy outcomes included:

• Investigator's Global Assessment (IGA): A significantly higher proportion of patients treated with abrocitinib achieved a score of "clear" (0) or "almost clear" (1) with at least a 2-point improvement from baseline. In a pooled analysis, abrocitinib was more than twice as likely as placebo to achieve this outcome. For instance, one study reported that 26% of patients on the 100 mg dose and 41% on the 200 mg dose achieved clear or almost clear skin, compared to only 8% of patients on placebo.
• Eczema Area and Severity Index (EASI-75): Patients on abrocitinib were significantly more likely to achieve at least a 75% reduction in their EASI score from baseline. A meta-analysis found that abrocitinib recipients were nearly three times more likely than placebo recipients to reach the EASI-75 milestone.
• Peak Pruritus Numerical Rating Scale (PP-NRS4): Abrocitinib provided rapid and substantial relief from itch, a key symptom of AD. A significantly greater proportion of patients achieved a clinically meaningful reduction of 4 or more points on the 11-point itch scale compared to placebo.

The JADE REGIMEN trial investigated the maintenance of response. In this study, patients who initially responded to abrocitinib were re-randomized to continue their dose or switch to placebo. The results showed that continuous therapy with abrocitinib was significantly more effective at preventing disease flares than placebo, establishing its role in long-term disease control.

Efficacy Endpoint (at Week 12)	Abrocitinib 200 mg	Abrocitinib 100 mg	Placebo	Source(s)
IGA 0/1 Response (% Patients)	38.1 - 48.4%	23.7 - 28.4%	7.9 - 11.8%
EASI-75 Response (% Patients)	61.0 - 62.7%	39.7 - 44.5%	11.8 - 12.0%
PP-NRS4 Response (% Patients)	55.3 - 57.2%	37.7 - 45.1%	11.5 - 14.8%

B. Comparative Effectiveness Analysis

Beyond placebo-controlled data, the clinical program for abrocitinib included a crucial head-to-head trial against the established biologic agent, dupilumab, providing invaluable data for clinical decision-making.

Head-to-Head vs. Dupilumab (JADE DARE)

The Phase 3b JADE DARE trial (NCT04345367) directly compared oral abrocitinib 200 mg once daily with subcutaneous dupilumab 300 mg every other week in adults with moderate-to-severe AD on a background of topical therapy. The trial was designed to assess superiority on key early endpoints.

The results established a clear clinical differentiator for abrocitinib: speed of onset.

• Superiority on Itch Relief: Abrocitinib was statistically superior to dupilumab in the proportion of patients achieving a ≥4-point improvement in itch (PP-NRS4) as early as Week 2.
• Superiority on Skin Clearance: Abrocitinib was also superior to dupilumab in the proportion of patients achieving a ≥90% improvement in EASI score (EASI-90) at Week 4.

This rapid action is a direct reflection of abrocitinib's pharmacology. As a small molecule inhibitor of an intracellular kinase, it can modulate cytokine signaling almost immediately upon reaching therapeutic concentrations in the body. In contrast, biologics like dupilumab are large proteins that work extracellularly and typically have a more gradual onset of effect. This difference establishes a distinct clinical profile for abrocitinib, making it a highly attractive option for patients suffering from acute, severe symptoms, particularly debilitating pruritus, who prioritize immediate relief.

Meta-Analyses and Network Analyses

Multiple systematic reviews and meta-analyses have compared the efficacy of the new oral JAK inhibitors (abrocitinib, upadacitinib) with the biologic dupilumab. These analyses consistently corroborate the findings from head-to-head trials:

• Abrocitinib (200 mg) and upadacitinib (30 mg) are superior to dupilumab in achieving rapid improvements in both skin clearance (EASI-75) and itch relief (PP-NRS4) at week 2.
• At later time points (week 12 to 16), the higher doses of abrocitinib and upadacitinib are associated with efficacy outcomes that are slightly better than or comparable to dupilumab. The lower 100 mg dose of abrocitinib is generally associated with slightly lower efficacy than dupilumab.
• These analyses also introduce a critical part of the comparative discussion: safety. One meta-analysis noted a higher rate of severe adverse events in the combined abrocitinib/upadacitinib group compared to dupilumab, although rates of serious adverse events leading to treatment discontinuation were similar. This positions the therapeutic choice as a balance between the rapid efficacy of oral JAK inhibitors and the established long-term safety profile of an injectable biologic.

Comparative Endpoint	Abrocitinib 200 mg vs. Dupilumab	Time Point	Source(s)
PP-NRS4 (Itch Response)	Superior	Week 2
EASI-90 (Skin Clearance)	Superior	Week 4
EASI-90 (Skin Clearance)	Non-inferior	Week 16

C. Long-Term and Real-World Evidence

The JADE EXTEND study provided data on the long-term maintenance of efficacy and safety of abrocitinib. Furthermore, emerging real-world evidence is beginning to confirm the robust efficacy seen in controlled clinical trials. A retrospective study tracking patients for one year found that the effectiveness of abrocitinib was comparable to or even exceeded the rates observed in the Phase 3 trials. In this cohort, after 52 weeks of treatment, 100% of patients on abrocitinib achieved EASI-75, and 91.7% achieved EASI-90, demonstrating durable disease control in a clinical practice setting.

From an economic perspective, a cost-effectiveness analysis conducted from the Japanese healthcare payer perspective found abrocitinib to be a cost-effective option compared to the standard of care for adults with moderate-to-severe AD. The study reported an incremental cost-effectiveness ratio (ICER) of ¥3,034,514 (approximately $23,076 U.S.) per quality-adjusted life year (QALY) gained, a value generally considered acceptable within many healthcare systems.

Clinical Use and Prescribing Guidelines

The clinical application of abrocitinib requires a thorough understanding of its approved indications, dosing regimens, necessary monitoring, and potential for interactions with other medications and patient-specific conditions.

A. Approved Indications and Dosage Regimens

The approved indications for abrocitinib have subtle but important differences across major regulatory jurisdictions, reflecting different interpretations of the risk-benefit profile.

• U.S. Food and Drug Administration (FDA): In the United States, CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable. This more restrictive language positions it as a later-line therapy.
• European Medicines Agency (EMA): In the European Union, Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents from 12 years of age who are candidates for systemic therapy. This broader indication allows for its use earlier in the treatment algorithm.

Recommended Dosage and Administration

• Starting Dose: The recommended starting dosage is 100 mg orally once daily.
• Dose Escalation: For patients who do not achieve an adequate response after 12 weeks of treatment, the dosage may be increased to 200 mg orally once daily.
• Treatment Discontinuation: If an adequate response is still not achieved with the 200 mg daily dose, therapy should be discontinued.
• Maintenance: Once control is achieved, the lowest effective dose should be used to maintain the response.
• Administration: Abrocitinib tablets should be swallowed whole with water and should not be crushed, split, or chewed. They can be taken at approximately the same time each day, with or without food. Taking the medication with food may help mitigate potential nausea.

Limitations of Use

A critical limitation specified on the label is that abrocitinib is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators (e.g., dupilumab), or other potent immunosuppressants (e.g., cyclosporine, methotrexate). It can, however, be used concomitantly with topical corticosteroids.

B. Dosing in Special Populations and Management of Drug Interactions

The metabolism and clearance of abrocitinib necessitate specific dose adjustments in certain populations to ensure safety and efficacy.

• Renal Impairment:
• Mild (eGFR 60–89 mL/min): No dose adjustment needed.
• Moderate (eGFR 30–59 mL/min): The recommended dose is halved to 50 mg once daily. If response is inadequate, this may be increased to 100 mg once daily.
• Severe (eGFR <30 mL/min) and End-Stage Renal Disease: Use is not recommended.
• Hepatic Impairment:
• Mild to Moderate (Child-Pugh A or B): No dose adjustment needed.
• Severe (Child-Pugh C): Use is not recommended.
• CYP2C19 Poor Metabolizers: Patients with a known or suspected genetic deficiency in the CYP2C19 enzyme have reduced metabolic clearance and increased drug exposure. For these individuals, the recommended dose is 50 mg once daily, with a possible increase to 100 mg daily if the initial response is inadequate.
• Drug Interactions:
• Concomitant use with Strong CYP2C19 Inhibitors (e.g., fluconazole, fluvoxamine): The abrocitinib dose should be reduced to 50 mg once daily (with a potential increase to 100 mg) to avoid excessive drug exposure.
• Concomitant use with Strong CYP2C19 or CYP2C9 Inducers (e.g., rifampin): This combination should be avoided as it can significantly decrease abrocitinib concentrations and lead to a loss of efficacy.
• P-glycoprotein (P-gp) Substrates: Abrocitinib is an inhibitor of the P-gp transporter. Caution is advised when co-administering with P-gp substrates that have a narrow therapeutic index (e.g., digoxin), as abrocitinib may increase their concentrations.

Condition / Concomitant Drug	Recommended Abrocitinib Dosage	Source(s)
Moderate Renal Impairment (eGFR 30-59)	50 mg daily, may titrate to 100 mg
Severe Renal Impairment (eGFR <30)	Not Recommended
Severe Hepatic Impairment (Child-Pugh C)	Not Recommended
Known CYP2C19 Poor Metabolizer	50 mg daily, may titrate to 100 mg
Use with Strong CYP2C19 Inhibitors	50 mg daily, may titrate to 100 mg
Use with Strong CYP2C19/2C9 Inducers	Avoid Concomitant Use

C. Required Pre-Treatment and Ongoing Monitoring

The potent immunomodulatory effects of abrocitinib mandate a rigorous protocol of screening before treatment initiation and continuous monitoring during therapy to mitigate potential risks.

Pre-Treatment Screening

Before a patient starts CIBINQO, the following evaluations are required:

• Infection Screening: Patients must be tested for latent and active tuberculosis (TB). They should also be screened for viral hepatitis B and C. Abrocitinib should not be initiated in patients with an active, serious infection.
• Hematology: A baseline complete blood count (CBC) is mandatory. Initiation is not recommended in patients with a platelet count <150,000/mm3, an absolute lymphocyte count (ALC) <500/mm3, an absolute neutrophil count (ANC) <1,000/mm3, or a hemoglobin value <8 g/dL.
• Lipid Panel: While not a strict requirement in the US label, obtaining a baseline lipid panel is recommended as JAK inhibitors can affect cholesterol levels.
• Immunizations: Patients should be brought up-to-date with all age-appropriate immunizations, including the herpes zoster (shingles) vaccine, before starting therapy. The use of live, attenuated vaccines is not recommended during treatment.

The extensive nature of these prescribing guidelines reveals a significant operational complexity for the clinician. Unlike an injectable biologic with a simpler dosing and monitoring schedule, abrocitinib requires careful consideration of patient-specific factors (renal function, genetics), potential drug interactions, and a commitment to regular lab monitoring. This complexity creates a higher barrier to prescribing and may influence its adoption, potentially positioning it as a drug managed primarily by specialists for patients in whom other, less complex therapies have failed or are not appropriate.

In-Depth Safety Profile and Risk Management

The safety profile of abrocitinib is a critical component of its overall clinical evaluation. It is characterized by a range of common, manageable side effects and a series of rare but serious risks that are highlighted in a prominent Boxed Warning, a feature common to the entire class of oral JAK inhibitors.

A. Deconstruction of the FDA Boxed Warning

The U.S. FDA label for CIBINQO includes a Boxed Warning, the agency's most stringent warning, to alert prescribers and patients to significant risks. This warning is largely based on data from a postmarketing safety study of another JAK inhibitor, tofacitinib, in an older population of patients with rheumatoid arthritis (RA) who had at least one cardiovascular risk factor. The risks are considered class-wide and include:

1. Serious Infections:

• Patients treated with abrocitinib are at an increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that can lead to hospitalization or death.
• The most frequently reported serious infections in abrocitinib clinical trials were herpes simplex, herpes zoster (shingles), and pneumonia.
• There is a risk of reactivation of latent tuberculosis (TB). All patients must be screened for TB prior to starting therapy and monitored for signs of active TB during treatment, even if their initial test was negative.
• Viral reactivation, particularly of the herpes virus family, is a key concern. If a patient develops herpes zoster, interruption of abrocitinib therapy should be considered until the episode resolves.

2. Mortality:

• The RA safety study of another JAK inhibitor showed a higher rate of all-cause mortality, including sudden cardiovascular death, compared to patients treated with TNF blockers. Abrocitinib is not approved for the treatment of RA.

3. Malignancy and Lymphoproliferative Disorders:

• Malignancies have been reported in patients treated with abrocitinib. The JAK inhibitor class has been associated with lymphomas and other cancers, including lung and non-melanoma skin cancers (NMSC).
• The risk is noted to be higher in current or past smokers. Patients should undergo periodic skin examinations and be counseled on limiting sun and UV exposure.

4. Major Adverse Cardiovascular Events (MACE):

• In the RA safety study population, a higher rate of MACE—defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke—was observed in the JAK inhibitor group compared to the TNF blocker group.
• Current or past smokers are at an additional increased risk. It is recommended to discontinue abrocitinib in patients who experience an MI or stroke.

5. Thrombosis:

• Events of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with abrocitinib and other JAK inhibitors. The RA safety study also showed a higher rate of thrombosis events for the JAK inhibitor class. Abrocitinib should be avoided in patients who may be at increased risk of thrombosis.

A central challenge in clinical practice is interpreting these risks. The data driving the warning came from an older, sicker RA population (age ≥50 with CV risk factors), which is demographically distinct from the typical AD population, which includes adolescents and younger adults (mean age in trials ~37 years) with fewer comorbidities. This creates a "data gap," where the true incidence of these serious events in the AD population is not yet fully quantified. The FDA has taken a conservative, class-wide approach, which makes patient selection and a thorough shared decision-making conversation about these potential risks paramount. Long-term prospective safety data in the AD population are critically needed to refine this risk assessment.

B. Comprehensive Review of Adverse Reactions

Beyond the risks in the Boxed Warning, clinical trials have identified a profile of more common adverse events.

• Most Common Adverse Reactions (reported in ≥1% of patients):
• Gastrointestinal: Nausea (the most common), vomiting, upper abdominal pain.
• Infections: Nasopharyngitis (common cold), urinary tract infection, herpes simplex (including cold sores), influenza, impetigo.
• Neurological: Headache, dizziness.
• General: Fatigue.
• Dermatological: Acne, contact dermatitis.
• Laboratory: Increased blood creatine phosphokinase.
• Laboratory Abnormalities:
• Hematologic: Abrocitinib can cause dose-related decreases in platelet counts (thrombocytopenia) and lymphocyte counts (lymphopenia). Dose interruption or discontinuation is recommended if counts fall below pre-specified thresholds for platelets, absolute lymphocytes (ALC), or absolute neutrophils (ANC).
• Lipids: Dose-related increases in LDL-cholesterol, HDL-cholesterol, and total cholesterol levels have been observed, necessitating periodic monitoring.
• Hepatic Enzymes: Transient and usually mild elevations in serum aminotransferase levels (ALT, AST) can occur in a small percentage of patients. To date, abrocitinib has not been linked to cases of clinically apparent, severe drug-induced liver injury.

Safety Concern	Description	Source(s)
Boxed Warning	Increased risk of: Serious Infections, All-Cause Mortality, Malignancy, Major Adverse Cardiovascular Events (MACE), and Thrombosis.
Common AEs (≥1%)	Nausea, nasopharyngitis, headache, herpes simplex, increased CPK, dizziness, UTI, fatigue, acne, vomiting.
Other Significant AEs	Herpes zoster, thrombocytopenia, hypertension.
Lab Abnormalities	Decreased platelets, lymphocytes, neutrophils. Increased cholesterol levels.

C. Contraindications and Use in Specific Populations

• Contraindications: CIBINQO is contraindicated in patients taking antiplatelet therapies (with the exception of low-dose aspirin, ≤81 mg daily) during the first 3 months of treatment. This is a specific precaution related to the observed effects on platelets.
• Pregnancy and Lactation: Due to a lack of sufficient human data and potential for risk, breastfeeding is not recommended during treatment and for one day after the last dose. Pfizer has established a CIBINQO Pregnancy Exposure Registry to collect prospective data on the outcomes of pregnant women exposed to the drug.

Regulatory and Commercial Landscape

A. Global Regulatory Approvals

Abrocitinib has successfully navigated the regulatory review process in major markets worldwide, though with some regional variations in the approved indication.

• United Kingdom (MHRA) and Japan (PMDA): Abrocitinib received its first approvals in these regions in September 2021 for the treatment of moderate-to-severe AD in adults and adolescents.
• European Union (EMA): The European Commission granted marketing authorisation on December 10, 2021, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on October 14, 2021. The indication is for adults and adolescents with moderate-to-severe AD who are candidates for systemic therapy. The drug is placed under "additional monitoring" to gather more safety data post-launch.
• United States (FDA): The FDA approved CIBINQO on January 14, 2022. The path to approval included a Breakthrough Therapy Designation in 2018 and Priority Review status in 2020, signaling its potential to address an unmet medical need. The initial approval was for adults, and this was expanded in February 2023 to include adolescents aged 12 and older with refractory disease.
• China (NMPA): Approval was granted in 2024.

B. Manufacturer and Patient Support

• Developer and Manufacturer: Abrocitinib was developed and is manufactured by Pfizer Inc., a global pharmaceutical company.
• Patient Support Programs: Recognizing the potential cost and complexity of treatment, Pfizer has established comprehensive support systems for patients. In the U.S., the Pfizer Dermatology Patient Access™ program offers several resources :
• CIBINQO Copay Savings Card: For eligible patients with commercial insurance, this card helps reduce out-of-pocket prescription costs, up to an annual maximum benefit.
• Pfizer Patient Assistance Program: This program may provide free medicine to eligible uninsured or underinsured patients who meet certain income and other criteria.
• Patient Education and Resources: Pfizer provides a suite of downloadable materials for patients and caregivers, including a doctor discussion guide, information on required lab testing, and a digital eczema tracker to help monitor disease progress. These resources are designed to facilitate informed conversations with healthcare providers and empower patients to take an active role in their treatment journey.

Emerging and Investigational Applications

The targeted immunomodulatory mechanism of abrocitinib, centered on JAK1 inhibition, suggests its potential utility in a range of other inflammatory and autoimmune conditions beyond atopic dermatitis. Research is actively exploring these new frontiers.

• Pediatric Peanut Allergy: Preclinical, in vitro studies have shown that abrocitinib can decrease the activation of T-cells and allergen-specific basophils in response to peanut allergens. This suggests a potential role for abrocitinib as either an adjunctive immunomodulator to enhance the safety and efficacy of oral immunotherapy or, potentially, as a standalone monotherapy for certain food allergies.
• Oral Lichen Planus (OLP): OLP is a chronic T-cell-mediated inflammatory disease of the oral mucosa. A 2022 clinical case report documented the rapid and complete resolution of erosive OLP in a patient treated with abrocitinib 200 mg daily for 12 weeks. The treatment was well-tolerated and resulted in significant improvement of lesions, offering a proof-of-concept for its use in this condition.
• Necrobiosis Lipoidica: A case report has described the successful use of abrocitinib in improving the lesions of necrobiosis lipoidica, a chronic granulomatous skin disease. Treatment led to a decrease in the inflammatory borders and an overall improvement in the appearance of the lesions.
• Type 1 Diabetes Mellitus (T1D): There is growing interest in using JAK inhibitors to halt the autoimmune destruction of pancreatic beta cells in T1D. A Phase 2 clinical trial (NCT05743244) is actively recruiting patients with new-onset T1D to investigate whether abrocitinib and another JAK inhibitor can preserve endogenous insulin production, as measured by C-peptide levels.
• Other Autoimmune and Inflammatory Diseases: Abrocitinib has been evaluated in other conditions. A Phase 2 trial for plaque psoriasis was completed, but further development for this indication was halted by Pfizer for business reasons, not for lack of efficacy or safety concerns. Clinical trials have also been initiated or completed for granuloma annulare and sarcoidosis. Furthermore, preclinical animal data demonstrated efficacy in a rat model of adjuvant-induced arthritis, which supported its initial development as a treatment for autoimmune diseases more broadly.
• Neuroprotection: Intriguing preclinical evidence suggests a potential neuroprotective role for abrocitinib. In mouse models of traumatic brain injury (TBI), treatment with abrocitinib was shown to improve neurological function. This effect is hypothesized to be mediated by the restraint of the pro-inflammatory JAK1/STAT1/NF-κB signaling pathway and the modulation of microglia activation from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype.

Expert Analysis and Strategic Outlook

Synthesis of the Benefit-Risk Profile

Abrocitinib has firmly established itself as a highly effective, rapid-acting oral therapy for moderate-to-severe atopic dermatitis. Its clinical profile is defined by a compelling duality: its primary therapeutic benefit—unprecedented speed of itch relief and skin clearance—is counterbalanced by a significant, class-wide safety warning that necessitates careful and continuous clinical management. The core of the risk-benefit discussion revolves around the desire for immediate, life-altering symptom control versus the potential for rare but serious long-term adverse events. The fact that the most severe risks (MACE, malignancy, mortality) in the Boxed Warning are extrapolated from a different patient population (older RA patients) adds a layer of uncertainty that clinicians and patients must navigate together. For many patients suffering from the debilitating physical and psychosocial burden of severe AD, the demonstrated benefits may substantially outweigh these theoretical risks.

Defining the Place in Therapy

In the increasingly crowded AD treatment landscape, abrocitinib has carved out a distinct therapeutic niche. Its primary competitor among systemic agents is the injectable biologic dupilumab, while its closest oral competitors are other JAK inhibitors, notably upadacitinib.

• Ideal Patient Profile: The ideal candidate for abrocitinib is likely a patient with moderate-to-severe AD characterized by intense, debilitating pruritus that severely impacts quality of life, particularly sleep. This patient would prioritize rapid symptom relief and be willing to accept the required laboratory monitoring and the potential long-term risks outlined in the Boxed Warning. The restrictive U.S. label positions it for patients who have already failed other systemic therapies, including biologics, making it a key option for the most difficult-to-treat cases.
• Competitive Positioning:
• vs. Dupilumab: The choice is one of speed vs. safety profile. Abrocitinib offers superior speed of onset, oral administration, and strong efficacy. Dupilumab offers a well-established long-term safety record, less intensive monitoring requirements, and a different mechanism of action, but with a slower onset and subcutaneous administration.
• vs. Upadacitinib: This comparison is more nuanced, as both are oral JAK inhibitors with similar rapid efficacy and the same Boxed Warning. The choice may come down to subtle differences in dose-response curves, specific side-effect profiles observed in clinical trials, physician experience, and formulary access.

Unanswered Questions and Future Research Directions

Despite its successful clinical development, several critical questions remain that will shape the future of abrocitinib.

1. Long-Term Safety in the AD Population: The most pressing need is for long-term, prospective, real-world safety data specifically from the atopic dermatitis population. Such data are essential to accurately quantify the true incidence of MACE, malignancy, thrombosis, and mortality in this younger, generally healthier patient group, which will allow for a more precise understanding of the benefit-risk equation.
2. Direct Comparative Effectiveness: While the JADE DARE trial provided a head-to-head comparison with dupilumab, more comparative studies are needed, particularly against other JAK inhibitors and emerging therapies, to better define relative efficacy and safety.
3. Role of Pharmacogenomics: The label recommends dose adjustments for CYP2C19 poor metabolizers. Future research should focus on the clinical utility and cost-effectiveness of routine genotyping to proactively identify these patients and optimize dosing from the outset.
4. Exploration of Investigational Indications: The potential for label expansion into areas like food allergy, type 1 diabetes, or other dermatologic conditions is significant. Successful development in these areas could dramatically expand the drug's clinical value and market potential.
5. Pediatric Development: Clinical trials in younger pediatric cohorts (e.g., 6 to <12 years, NCT06807268) are underway. Establishing safety and efficacy in these populations is a key next step for expanding its use.

Concluding Remarks

Abrocitinib represents a paradigm shift in the management of moderate-to-severe atopic dermatitis. It has introduced the therapeutic expectation of rapid and profound relief from the disease's most burdensome symptoms, delivered in a convenient oral formulation. It is a powerful and important tool that has fundamentally altered treatment goals. However, this efficacy is paired with a complex safety profile and a high degree of management intensity. Its successful integration into clinical practice hinges on a foundation of rigorous patient selection, comprehensive education, and a commitment to shared decision-making, ensuring that its potent benefits are directed to the patients who need them most and can be treated safely.

Works cited

1. Abrocitinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 12, 2025, https://go.drugbank.com/drugs/DB14973
2. abrocitinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 12, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9991
3. Abrocitinib Uses, Side Effects & Warnings - Drugs.com, accessed August 12, 2025, https://www.drugs.com/mtm/abrocitinib.html
4. Abrocitinib - Wikipedia, accessed August 12, 2025, https://en.wikipedia.org/wiki/Abrocitinib
5. CIBINQO® (abrocitinib) | Once Daily Eczema Pill | Safety Info, accessed August 12, 2025, https://www.cibinqo.com/
6. Abrocitinib (PF-04965842) | JAK1 Inhibitor | MedChemExpress, accessed August 12, 2025, https://www.medchemexpress.com/Abrocitinib.html
7. Abrocitinib (PF-04965842, CAS Number: 1622902-68-4) | Cayman Chemical, accessed August 12, 2025, https://www.caymanchem.com/product/34869/abrocitinib
8. Abrocitinib: MedlinePlus Drug Information, accessed August 12, 2025, https://medlineplus.gov/druginfo/meds/a622008.html
9. Abrocitinib (oral route) - Side effects & dosage - Mayo Clinic, accessed August 12, 2025, https://www.mayoclinic.org/drugs-supplements/abrocitinib-oral-route/description/drg-20529411
10. CIBINQO® (abrocitinib) Description | Pfizer Medical - US, accessed August 12, 2025, https://www.pfizermedical.com/cibinqo-0/description
11. PF-04965842 (Abrocitinib) (CAS 1622902-68-4) (ab287063) | Abcam, accessed August 12, 2025, https://www.abcam.com/en-us/products/biochemicals/pf-04965842-abrocitinib-ab287063
12. Compound: ABROCITINIB (CHEMBL3655081) - ChEMBL - EMBL-EBI, accessed August 12, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3655081
13. CIBINQO (abrocitinib) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213871s001lbl.pdf
14. PF 04965842, Abrocitinib | New Drug Approvals, accessed August 12, 2025, https://newdrugapprovals.org/2019/08/05/pf-04965842-abrocitinib/
15. Abrocitinib | PF-04965842 | CAS#1622902-68-4 | Janus Kinase 1 inhibitor | MedKoo, accessed August 12, 2025, https://www.medkoo.com/products/15989
16. Abrocitinib - PubChem, accessed August 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Abrocitinib
17. abrocitinib - PubChem, accessed August 12, 2025, https://pubchem.ncbi.nlm.nih.gov/substance/374883878/version/5
18. abrocitinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 12, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=immuno&ligandId=9991
19. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d ... - ACS Publications, accessed August 12, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01598
20. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases | Journal of Medicinal Chemistry - ACS Publications, accessed August 12, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b01598
21. A Comprehensive Overview of Globally Approved JAK Inhibitors - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9146299/
22. Abrocitinib: Synthesis and Application - ChemicalBook, accessed August 12, 2025, https://www.chemicalbook.com/article/abrocitinib-synthesis-and-application.htm
23. Synthesis of Abrocitinib - Thieme Connect, accessed August 12, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1719731.pdf
24. www.chemicalbook.com, accessed August 12, 2025, https://www.chemicalbook.com/article/abrocitinib-synthesis-and-application.htm#:~:text=Synthesis%20of%20Abrocitinib&text=The%20synthesis%20began%20with%20commercially,%3A1%20cis%3Atrans%20ratio.
25. Abrocitinib (CIBINQO) in Atopic Dermatitis National Drug Monograph February 2023 | VA.gov, accessed August 12, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Abrocitinib_CIBINQO_in_Atopic_Dermatitis_Monograph_Feb_2023.pdf
26. CAS 1622902-68-4 Abrocitinib - BOC Sciences, accessed August 12, 2025, https://www.bocsci.com/abrocitinib-cas-1622902-68-4-item-286107.html
27. (PDF) Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/371410030_Efficacy_and_safety_of_abrocitinib_and_upadacitinib_versus_dupilumab_in_adults_with_moderate-to-severe_atopic_dermatitis_A_systematic_review_and_meta-analysis
28. Abrocitinib - LiverTox - NCBI Bookshelf, accessed August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK581695/
29. Cibinqo (abrocitinib) FDA Approval History - Drugs.com, accessed August 12, 2025, https://www.drugs.com/history/cibinqo.html
30. Abrocitinib Reduces Itch and Lesions in AD Trial - Dermatology Times, accessed August 12, 2025, https://www.dermatologytimes.com/view/abrocitinib-reduces-itch-and-lesions-in-ad-trial
31. Abrocitinib: First Approval - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8917037/
32. Annotation of FDA Label for abrocitinib and CYP2C19 - PharmGKB, accessed August 12, 2025, https://www.clinpgx.org/labelAnnotation/PA166272961
33. abrocitinib - PharmGKB, accessed August 12, 2025, https://www.clinpgx.org/chemical/PA166272921
34. Abrocitinib metabolite M1 | C14H21N5O3S | CID 162364434 - PubChem, accessed August 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Abrocitinib-metabolite-M1
35. 213871Orig1s000 - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/213871Orig1s000OtherR.pdf
36. Dosing & Monitoring - CIBINQO™ (abrocitinib), accessed August 12, 2025, https://cibinqo.pfizerpro.com/dosing-monitoring/dosing
37. Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy | ClinicalTrials.gov, accessed August 12, 2025, https://www.clinicaltrials.gov/study/NCT04345367
38. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/37332971/
39. Meta-analysis reveals that abrocitinib and upadacitinib top dupilumab in moderate-to-severe atopic dermatitis - The Hospitalist, accessed August 12, 2025, https://blogs.the-hospitalist.org/content/meta-analysis-reveals-abrocitinib-and-upadacitinib-top-dupilumab-moderate-severe-atopic
40. Review Finds Abrocitnib, Upadacitinib Superior to Dupilumab - HCPLive, accessed August 12, 2025, https://www.hcplive.com/view/abrocitnib-upadacitinib-surpass-dupilumab-easi-scores
41. Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in Patients With AD After 1 Year - Dermatology Times, accessed August 12, 2025, https://www.dermatologytimes.com/view/both-upadacitinib-and-abrocitinib-demonstrate-real-world-efficacy-in-ad-patients-after-1-year
42. Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Study - - PracticalDermatology, accessed August 12, 2025, https://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/
43. CIBINQO® (abrocitinib) Indications and Usage Patient information | Pfizer Medical - US, accessed August 12, 2025, https://www.pfizermedical.com/patient/cibinqo-0/indications-usage
44. Cibinqo | European Medicines Agency (EMA), accessed August 12, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo
45. Cibinqo (abrocitinib) dosing, indications, interactions, adverse effects, and more, accessed August 12, 2025, https://reference.medscape.com/drug/cibinqo-abrocitinib-4000159
46. 1 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatf, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf
47. CIBINQO™ (abrocitinib) | Oral Rx Option | Safety Info, accessed August 12, 2025, https://cibinqo.pfizerpro.com/
48. Taking CIBINQO® (abrocitinib) | Safety Info, accessed August 12, 2025, https://www.cibinqo.com/taking-cibinqo
49. FAQ - Cibinqo (Abrocitinib) - National Eczema Association, accessed August 12, 2025, https://nationaleczema.org/faq-cibinqo-abrocitinib/
50. abrocitinib - PharmGKB, accessed August 12, 2025, https://www.clinpgx.org/chemical/PA166272921/prescribingInfo
51. U.S. FDA Approves Pfizer's CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis, accessed August 12, 2025, https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults
52. CIBINQO® (abrocitinib) Boxed Warning | Pfizer Medical - US, accessed August 12, 2025, https://www.pfizermedical.com/cibinqo-0/boxed-warning
53. Safety and Side Effects | CIBINQO® (abrocitinib), accessed August 12, 2025, https://www.cibinqo.com/safety-and-side-effects
54. Find a Doctor Near You | CIBINQO® (abrocitinib) | Safety Info, accessed August 12, 2025, https://www.cibinqo.com/find-a-doctor
55. Financial Support - Pfizer Dermatology Patient Access, accessed August 12, 2025, https://www.pfizerdermatologypatientaccess.com/patients/financial-support
56. Downloadable Resources | CIBINQO® (abrocitinib) | Safety Info, accessed August 12, 2025, https://www.cibinqo.com/downloadable-resources
57. Abrocitinib Recruiting Phase 2 Trials for Type 1 Diabetes Mellitus Treatment - DrugBank, accessed August 12, 2025, https://go.drugbank.com/drugs/DB14973/clinical_trials?conditions=DBCOND0029465&phase=2&purpose=treatment&status=recruiting
58. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/29298069/
59. A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | ClinicalTrials.gov, accessed August 12, 2025, https://clinicaltrials.gov/study/NCT06807268